Shen Hao, Li Haifeng, Tang Haodong
Department of Thyroid Breast Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200120, China.
Department of Hepatic-Biliary-Pancreatic Center, Zhongda Hospital, Medical School, Southeast University, Nanjing 210000, China.
Cancer Cell Int. 2025 May 20;25(1):183. doi: 10.1186/s12935-025-03803-0.
Hepatocellular carcinoma (HCC) is recognized for its high growth rate, high degree of invasiveness, and tendency to spread, leading to a significant number of deaths. In the course of studying the transcriptome of HCC tissues, the protein coiled-coil domain-containing 110 (CCDC110) was identified. By employing tandem mass tag (TMT) quantitative proteomics, this research identified transforming growth factor beta receptor 1 (TGFBR1) as a potential target influenced by CCDC110. The purpose of this study was to examine the role of CCDC110 in the growth and invasion of HCC and to identify new potential targets for the treatment of HCC.
In vitro and in vivo experiments were conducted to investigate the role and mechanism of CCDC110 in promoting the malignant behaviors of hepatocellular carcinoma through the regulation of TGFBR1.
We determined that the mRNA and protein levels of CCDC110 are elevated in hepatocellular carcinoma tissues and cell lines, which is correlated with a worse patient prognosis. CCDC110 enhances the proliferation of hepatocellular carcinoma cells, reduces their apoptosis, and increases their migration and invasion capabilities. In the cytoplasm, CCDC110 interacts with TGFBR1, enhancing stability of TGFBR1, promoting proliferation, and reducing the apoptosis, migration, and invasion of hepatocellular carcinoma cells through TGFBR1 both in vivo and in vitro. The CCDC110-TGFBR1 axis stimulates EMT, thereby enhancing the malignant biological behavior of hepatocellular carcinoma by activating the TGF-β/SMAD signaling pathway. The protein levels of CCDC110/TGFBR1 in hepatocellular carcinoma tissues are highly expressed and positively correlated. A combined analysis of CCDC110 and TGFBR1 provides improved guidance for the prognosis of patients with hepatocellular carcinoma.
CCDC110 is highly expressed in hepatocellular carcinoma tissues and cell lines, and the CCDC110-TGFBR1 axis facilitates EMT and the malignant biological behavior of hepatocellular carcinoma through the activation of the TGF-β/SMAD signaling pathway.
肝细胞癌(HCC)以其高生长速率、高侵袭性和转移倾向而闻名,导致大量死亡。在研究HCC组织转录组的过程中,鉴定出了含卷曲螺旋结构域蛋白110(CCDC110)。本研究通过采用串联质谱标签(TMT)定量蛋白质组学,确定转化生长因子β受体1(TGFBR1)是受CCDC110影响的潜在靶点。本研究的目的是探讨CCDC110在HCC生长和侵袭中的作用,并确定治疗HCC的新潜在靶点。
进行体外和体内实验,以研究CCDC110通过调节TGFBR1促进肝细胞癌恶性行为的作用及机制。
我们确定CCDC110的mRNA和蛋白水平在肝细胞癌组织和细胞系中升高,这与患者较差的预后相关。CCDC110增强肝细胞癌细胞的增殖,减少其凋亡,并增加其迁移和侵袭能力。在细胞质中,CCDC110与TGFBR1相互作用,增强TGFBR1的稳定性,促进增殖,并通过TGFBR1在体内外减少肝细胞癌细胞的凋亡、迁移和侵袭。CCDC110-TGFBR1轴刺激上皮-间质转化(EMT),从而通过激活TGF-β/SMAD信号通路增强肝细胞癌的恶性生物学行为。肝细胞癌组织中CCDC110/TGFBR1的蛋白水平高表达且呈正相关。CCDC110和TGFBR1的联合分析为肝细胞癌患者的预后提供了更好的指导。
CCDC110在肝细胞癌组织和细胞系中高表达,CCDC110-TGFBR1轴通过激活TGF-β/SMAD信号通路促进EMT和肝细胞癌的恶性生物学行为。